Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus

Yuan, Wen-Jun; Guan, Fengjun

doi:10.1155/2022/3208037

Cited by 7 publications

(7 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anticoagulant therapies, such as Heparin and Warfarin, can block the vicious cycle between inflammation and thrombosis, which may greatly improve the long-term prognosis of patients with SLE [ 179 ]. Heparin is often used as an initial treatment.…”

Section: Management Of Npslementioning

confidence: 99%

See 1 more Smart Citation

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Justiz-Vaillant,

Gopaul,

Soodeen

et al. 2024

Molecules

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an idiopathic chronic autoimmune disease that can affect any organ in the body, including the neurological system. Multiple factors, such as environmental (infections), genetic (many HLA alleles including DR2 and DR3, and genes including C4), and immunological influences on self-antigens, such as nuclear antigens, lead to the formation of multiple autoantibodies that cause deleterious damage to bodily tissues and organs. The production of autoantibodies, such as anti-dsDNA, anti-SS(A), anti-SS(B), anti-Smith, and anti-neuronal DNA are characteristic features of this disease. This autoimmune disease results from a failure of the mechanisms responsible for maintaining self-tolerance in T cells, B cells, or both. Immune complexes, circulating antibodies, cytokines, and autoreactive T lymphocytes are responsible for tissue injury in this autoimmune disease. The diagnosis of SLE is a rheumatological challenge despite the availability of clinical criteria. NPSLE was previously referred to as lupus cerebritis or lupus sclerosis. However, these terms are no longer recommended because there is no definitive pathological cause for the neuropsychiatric manifestations of SLE. Currently, the treatment options are primarily based on symptomatic presentations. These include the use of antipsychotics, antidepressants, and anxiolytic medications for the treatment of psychiatric and mood disorders. Antiepileptic drugs to treat seizures, and immunosuppressants (e.g., corticosteroids, azathioprine, and mycophenolate mofetil), are directed against inflammatory responses along with non-pharmacological interventions.

show abstract

Section: Management Of Npslementioning

confidence: 99%

“…There is less evidence available on the use of Warfarin in patients with SLE. However, a prospective multicenter research trial showed that Warfarin (1–5 mg/day) started at the same time as a steroid therapy for at least 3 months can prevent the occurrence of osteonecrosis associated with SLE [ 179 ].…”

Section: Management Of Npslementioning

confidence: 99%

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Justiz-Vaillant,

Gopaul,

Soodeen

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…bei Patienten mit überlappendem SLE und 3-fach positiven aPL [105]. Eine primäre Thromboseprophylaxe mit Antikoagulanzien wird bei SLE-Patienten nicht empfohlen [106, 107], während eine langfristige Sekundärprophylaxe in Abhängigkeit vom Nutzen-Risiko-Verhältnis erwogen werden sollte.…”

Section: Antikoagulation Bei Patienten Mit Autoimmunerkrankungenunclassified

Risiko venöser Thromboembolien bei Autoimmunerkrankungen: Eine umfassende Übersicht

Menichelli,

Cormaci,

Marucci

et al. 2024

Kompass Autoimmun

View full text Add to dashboard Cite

Autoimmunerkrankungen haben spezifische pathophysiologische Mechanismen, die zu einem erhöhten Risiko für arterielle und venöse Thrombosen führen. Das Risiko einer venösen Thromboembolie (VTE) variiert je nach Art und Stadium der Erkrankung sowie der begleitenden Therapie. In dieser Übersichtsarbeit werden die häufigsten Autoimmunerkrankungen wie Anti-Phospholipid-Syndrom, entzündliche Myositis, Polymyositis und Dermatomyositis, rheumatoide Arthritis, Sarkoidose, Sjögren-Syndrom, autoimmunhämolytische Anämie, systemischer Lupus erythematodes, systemische Sklerose, Vaskulitis und chronisch-entzündliche Darmerkrankungen behandelt. Darüber hinaus geben wir einen Überblick über die Pathophysiologie, die für das VTE-Risiko bei jeder Autoimmunerkrankung verantwortlich ist, und berichten über die aktuellen Indikationen für eine gerinnungshemmende Therapie zur Primär- und Sekundärprävention von VTE.

show abstract

“…is a systemic autoimmune disease with vascular lesions. Its clinical manifestations vary from mild cutaneous and mucosal diseases to multiple organ involvement [ 92 ].…”

Section: Prospectmentioning

confidence: 99%

The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions

Yang

Luo

Lai

2022

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary CD5L/AIM(apoptosis inhibitor of macrophage), as an important component in maintaining tissue homeostasis and inflammation, is mainly produced and secreted by macrophages but partially dissociated and released from blood AIM-IgM. AIM plays a regulatory role in intracellular physiological mechanisms, including lipid metabolism and apoptosis. AIM not only increases in autoimmune diseases, directly targets liver cells in liver cancer and promotes cell clearance in acute kidney injury, but also causes arteriosclerosis and cardiovascular events, and aggravates inflammatory reactions in lung diseases and sepsis. Obviously, AIM plays a pleiotropic role in the body. However, to date, studies have failed to decipher the mechanisms behind its different roles (beneficial or harmful) in inflammatory regulation.The inflammatory response is a "double-edged sword," and maintaining balance is critical for effective host defense while minimizing the adverse side effects of acute inflammation. Enhancing the understanding of AIM function could provide the theoretical basis for new therapies in these pathological settings. In this review, we discuss recent studies on the roles of AIM in lipid metabolism, autoimmune diseases and organic tissues, such as liver cancer, myocardial infarction, and kidney disease.

show abstract

Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus

Cited by 7 publications

References 93 publications

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Risiko venöser Thromboembolien bei Autoimmunerkrankungen: Eine umfassende Übersicht

The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions

Contact Info

Product

Resources

About